Merck
  • Home
  • Search Results
  • Functional characterisation and permeation studies of lyophilised thiolated chitosan xerogels for buccal delivery of insulin.

Functional characterisation and permeation studies of lyophilised thiolated chitosan xerogels for buccal delivery of insulin.

Protein and peptide letters (2014-08-08)
Joshua S Boateng, John C Mitchell, Harshavardhan Pawar, Isaac Ayensu
ABSTRACT

Stable and mucoadhesive, lyophilised, thiolated chitosan xerogels, loaded with insulin for buccal mucosa deliv- ery, in place of the currently used parenteral route have been developed. The xerogels were backed with impervious ethyl- cellulose laminate to ensure unidirectional release and also loaded with enzyme inhibitor to enhance insulin permeability across the buccal mucosa. Characterisation of xerogels using(1) HNMR confirmed the degree of deacetylation of the syn- thesised thiolated chitosan. The amount of thiol groups immobilised on the modified chitosan was quantified by Ellman's reaction and molecular weight monitored by gel permeation chromatography. The stability of the secondary structure of insulin was examined by attenuated total reflectance Fourier transform infra-red spectroscopy and circular dichroism. In vitro and ex vivo permeation studies were undertaken by using EpiOral ™ and sheep buccal membrane respectively. Insu- lin released from thiolated chitosan xerogels, loaded with aprotinin (enzyme inhibitor and permeation enhancer) showed a 1.7-fold increase in permeation through EpiOral ™ buccal tissue construct compared to the pure drug. However, permea- tion was decreased for xerogels containing the enzyme inhibitor glutathione. Further, aprotinin containing xerogels en- hanced insulin permeation through sheep buccal membrane and demonstrated good linear correlation with the permeation data from the EpiOral ™ study. The results show the potential application of lyoph ilised thiolated chitosan xerogels con- taining aprotinin with improved mucoadhesion, penetration enhancing and enzyme inhibition characteristics for buccal mucosa delivery of macromolecules such as insulin.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
LUDOX® HS-30 colloidal silica, 30 wt. % suspension in H2O
Sigma-Aldrich
LUDOX® CL colloidal silica, 30 wt. % suspension in H2O
Supelco
Glycerin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Silica, nanopowder, spec. surface area 175-225 m2/g (BET), 99.8% trace metals basis
Sigma-Aldrich
Silica, nanoparticles, mesoporous, 200 nm particle size, pore size 4 nm
Supelco
Silica, 99.8%
Sigma-Aldrich
1-Naphthyl phosphate monosodium salt monohydrate, ≥98% (titration), powder
Sigma-Aldrich
Silica
Sigma-Aldrich
Thioglycolic acid, ≥97%
Sigma-Aldrich
Silicon dioxide, −325 mesh, 99.5% trace metals basis
Sigma-Aldrich
LUDOX® TM-40 colloidal silica, 40 wt. % suspension in H2O
Sigma-Aldrich
LUDOX® LS colloidal silica, 30 wt. % suspension in H2O
Sigma-Aldrich
LUDOX® SM colloidal silica, 30 wt. % suspension in H2O
Sigma-Aldrich
Silicon dioxide, fused (pieces), 4 mm, 99.99% trace metals basis
Sigma-Aldrich
Silicon dioxide, fused (granular), 4-20 mesh, 99.9% trace metals basis
Supelco
Glass spheres
Sigma-Aldrich
Thioglycolic acid, ≥99%
Sigma-Aldrich
Silica, fumed, powder
Sigma-Aldrich
Thioglycolic acid, 98%
Sigma-Aldrich
Glycerin, meets USP testing specifications
Sigma-Aldrich
Silicon dioxide, acid washed and calcined, Analytical Reagent
Sigma-Aldrich
Silicon dioxide, washed and calcined, analytical reagent
Sigma-Aldrich
Glycerol solution, 83.5-89.5% (T)
Sigma-Aldrich
Silicon dioxide, acid washed
Sigma-Aldrich
Silicon dioxide, granular, ≥99.9%
Sigma-Aldrich
Silica, mesostructured, MSU-F (cellular foam)
Sigma-Aldrich
Silica, fumed, powder, 0.2-0.3 μm avg. part. size (aggregate)
Sigma-Aldrich
Glycerol solution, puriss., meets analytical specification of Ph. Eur., BP, 84-88%
Sigma-Aldrich
Silicon dioxide, purum p.a., acid purified, sand
Sigma-Aldrich
Silicon dioxide, purum p.a., acid purified